Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016

  • ID: 3674255
  • Report
  • 124 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Molecular Partners AG
  • Novartis AG
  • MORE
Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016

Summary

‘Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Review, H1 2016’, provides an overview of the Metastatic Hepatocellular Carcinoma (HCC) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Hepatocellular Carcinoma (HCC) and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Hepatocellular Carcinoma (HCC)
- The report reviews pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Hepatocellular Carcinoma (HCC) therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Hepatocellular Carcinoma (HCC) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Hepatocellular Carcinoma (HCC)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Hepatocellular Carcinoma (HCC)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Hepatocellular Carcinoma (HCC) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acceleron Pharma, Inc.
  • Celgene Corporation
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Molecular Partners AG
  • Novartis AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Metastatic Hepatocellular Carcinoma (HCC) Overview

Therapeutics Development

Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Overview

Pipeline Products for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis

Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Development by Companies

Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics under Investigation by Universities/Institutes

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline Products Glance

Clinical Stage Products

Early Stage Products

Metastatic Hepatocellular Carcinoma (HCC) - Products under Development by Companies

Metastatic Hepatocellular Carcinoma (HCC) - Products under Investigation by Universities/Institutes

Metastatic Hepatocellular Carcinoma (HCC) - Companies Involved in Therapeutics Development

Acceleron Pharma, Inc.

AstraZeneca Plc

AVEO Pharmaceuticals, Inc.

Celgene Corporation

Eli Lilly and Company

F. Hoffmann-La Roche Ltd.

HanAll Biopharma Co., Ltd.

Incuron, LLC

Johnson & Johnson

Mirna Therapeutics, Inc.

Molecular Partners AG

MolMed S.p.A.

Novartis AG

OncoMed Pharmaceuticals, Inc.

Pfizer Inc.

PharmAbcine, Inc.

Verlyx Pharma Inc.

Metastatic Hepatocellular Carcinoma (HCC) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AV-203 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AZD-9150 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-122 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cellular Immunotherapy for Metastatic Hepatocellular Carcinoma - Drug Profile

Product Description

Mechanism of Action

R&D Progress

codrituzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

dalantercept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

emibetuzumab - Drug Profile

Product Description

Mechanism of Action

R&D Progress

erdafitinib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

HL-143 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ipafricept - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LY-3039478 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

LY-3127804 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

mepacrine - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MP-0250 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MRX-34 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NGR-hTNF - Drug Profile

Product Description

Mechanism of Action

R&D Progress

OSU-2S - Drug Profile

Product Description

Mechanism of Action

R&D Progress

palbociclib - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pasireotide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

pentamidine isethionate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

PF-04518600 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sonidegib phosphate - Drug Profile

Product Description

Mechanism of Action

R&D Progress

temsirolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TTAC-0001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Metastatic Hepatocellular Carcinoma (HCC) - Recent Pipeline Updates

Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects

Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products

Metastatic Hepatocellular Carcinoma (HCC) - Product Development Milestones

Featured News & Press Releases

Nov 20, 2014: ISIS-STAT3 Rx Data Presented by AstraZeneca at European Cancer Symposium

Jul 30, 2013: Mirna Therapeutics Announces Important Expansion of microRNA Patent Portfolio

May 13, 2013: Marina Biotech's Licensee Mirna Therapeutics Initiates Phase I Clinical Trial Of Anticancer Drug MRX34

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2016

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Acceleron Pharma, Inc., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AstraZeneca Plc, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by AVEO Pharmaceuticals, Inc., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Celgene Corporation, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Eli Lilly and Company, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by HanAll Biopharma Co., Ltd., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Incuron, LLC, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Johnson & Johnson, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Mirna Therapeutics, Inc., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Molecular Partners AG, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by MolMed S.p.A., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Novartis AG, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Pfizer Inc., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by PharmAbcine, Inc., H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Pipeline by Verlyx Pharma Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) Therapeutics - Recent Pipeline Updates, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Dormant Projects, H1 2016

Metastatic Hepatocellular Carcinoma (HCC) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC), H1 2016

Number of Products under Development for Metastatic Hepatocellular Carcinoma (HCC) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Acceleron Pharma, Inc.
AstraZeneca Plc
AVEO Pharmaceuticals, Inc.
Celgene Corporation
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
HanAll Biopharma Co., Ltd.
Incuron, LLC
Johnson & Johnson
Mirna Therapeutics, Inc.
Molecular Partners AG
MolMed S.p.A.
Novartis AG
OncoMed Pharmaceuticals, Inc.
Pfizer Inc.
PharmAbcine, Inc.
Verlyx Pharma Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll